当前位置: X-MOL 学术Mol. Cancer Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Selected Articles from This Issue
Molecular Cancer Therapeutics ( IF 5.3 ) Pub Date : 2020-09-01
American Association for Cancer Research

### [Skidmore et al. Page 1833][1] ARX788, a site-specific next-generation anti-HER2 ADC, employs an unnatural amino acid to conjugate cytotoxic drug with a highly stable oxime bond, resulting in superior stability and an extended half-life of 12.5 days in mice. In xenograft and PDX animal models,

中文翻译:

本期精选文章

### [Skidmore等。Page 1833] [1] ARX788是一种位点特异性的下一代抗HER2 ADC,它使用一种非天然氨基酸来结合具有高度稳定的肟键的细胞毒性药物,从而具有出色的稳定性,并在12.5天内延长了半衰期12.5天。老鼠。在异种移植和PDX动物模型中,
更新日期:2020-09-02
down
wechat
bug